Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

Dr Kantarjian on the Predictive Value of Early Responses to Ponatinib in CP-CML

September 7th 2023

Hagop M. Kantarjian, MD, discusses the predictive value of early landmark cytogenetic or molecular responses to ponatinib in heavily pretreated patients with chronic-phase chronic myeloid leukemia.

Blood Cancer © laszlo - stock.adobe.com

Understanding How to Best Measure MRD Negativity in Ph+ ALL

September 7th 2023

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

Mark J. Roschewski, MD

PhaseEd-Seq MRD Detection May Provide Effective Alternative to Standard Imaging in LBCL

September 7th 2023

Current research suggests that circulating tumor DNA may have prognostic value when conducted at the conclusion of treatment in large B-cell lymphoma, indicating that minimal residual disease detection using ctDNA assessments such as PhaseEd-Seq could address imitations associated with the use of computed tomography or positron emission tomography/CT scans at this stage.

Hagop M. Kantarjian, MD

Early Cytogenetic or Molecular Landmark Response to Ponatinib Predicts Outcomes in CP-CML

September 7th 2023

Early cytogenetic and molecular responses achieved with ponatinib was significantly linked with better long-term progression-free survival and overall survival in patients with highly resistant, pretreated chronic-phase chronic myeloid leukemia.

Marisol Miranda-Galvis, DDS, MS, PhD

Health Outcomes in Hematologic Malignancies Impacted By Insurance, Marital, and Economic Status

September 7th 2023

Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status.

Guillermo Garcia-Manero, MD

Luspatercept Displays Superiority Over ESA in RBC Transfusion-Dependent MDS

September 7th 2023

The phase 3 COMMANDS trial investigating the use of luspatercept in patients with myelodysplastic syndrome who had not received an erythropoiesis-stimulating agent and were red blood cell transfusion dependent achieved its primary end point of superiority over treatment with an erythropoiesis-stimulating agent.

Blood Cancer | Image Credit: © fresh idea - stock.adobe.com

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

September 7th 2023

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Elias Jabbour, MD

Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL

September 6th 2023

The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Omar Shahin, MBChB

Outcomes With Pediatric-Inspired Regimens Warrant Further Exploration in AYA PH- ALL

September 6th 2023

Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

Bispecific Antibodies May Revolutionize the Management of B-Cell Lymphoma

September 6th 2023

The safety profiles and the high response rates observed with bispecific antibodies in patients with B-cell lymphoma suggest that these agents possess the potential to revolutionize the management of these diseases, particularly follicular lymphoma.

Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer

Dr Salgia on Clinical Gaps in the Development of Novel Targets in Lung Cancer

September 5th 2023

Ravi Salgia, MD, PhD, discusses clinical gaps in the development of novel targets in lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as potential strategies or steps to address these gaps in clinical practice.

Barbara Pistilli, MD

Novel ADCs Must Keep Up With Moving Targets in Metastatic Breast Cancer

August 22nd 2023

Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.

Erminia Massarelli, MD, PhD, MS

Dr Massarelli on Addressing Unmet Needs in SCLC

August 16th 2023

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Harry Gill, MD

Oral ATO/ATRA/Ascorbic Acid Regimen Delivers Durable Responses in APL

August 15th 2023

Harry Gill, MD, discusses the importance of offering patients with APL an entirely oral treatment regimen, key efficacy findings from this trial, and the tolerability of this regimen.

Edward S. Kim, MD, MBA

Dr Kim on the Bridging the Gaps in Lung Cancer Meeting

August 3rd 2023

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Alex Herrera, MD

Herrera Spotlights Key Research Across Hematologic Malignancies From the 2023 ASCO Annual Meeting

August 1st 2023

Alex Herrera, MD, discussed key data from the SWOG S1826 trial and other important research in hematologic malignancies presented at the 2023 ASCO Annual Meeting.

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO

Several Research Avenues Are Available for Improving Response to Immunotherapy in Advanced NSCLC

July 29th 2023

Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, highlights novel partners and potential new approaches for immunotherapy-based regimens for the treatment of patients with non–small cell lung cancer.

Karen Reckamp, MD

ADCs Offer Exciting Potential in Lung Cancer

July 29th 2023

Antibody-drug conjugates represent one of the most exciting areas of ongoing development for the treatment of patients with non–small cell lung cancer and small cell lung cancer.

Lyudmila A. Bazhenova, MD

Dr Bazhenova on Potential Combination Strategies With KRAS G12C Inhibitors in Advanced NSCLC

July 29th 2023

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Non–Small Cell Lung Cancer

Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC

July 29th 2023

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

Hatim Husain, MD

Dr Husain on Developments in ALK+ NSCLC

July 29th 2023

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Edgardo Santos, MD, FACP, FCCP

Dr Santos on Testing and Treatment in NRG1 Fusion–Positive NSCLC

July 29th 2023

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Edward S. Kim, MD, MBA

Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population

July 28th 2023

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

Solange Peters, MD, PhD

Tackling Resistance Mechanisms Is the Next Step in Immunotherapy Development for NSCLC

July 28th 2023

Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.

Primo “Lucky” Lara Jr., MD

Investigators Set Sights on Novel Agents Following Negative Studies in Relapsed Small Cell Lung Cancer

July 28th 2023

New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines.

Solange Peters, MD, PhD

Dr Peters on Understanding Mechanisms of Resistance to Immunotherapy in NSCLC

July 27th 2023

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Edward S. Kim, MD, MBA

Dr Kim on Improving Representation in Clinical Trials

July 27th 2023

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.